

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) The use of a therapeutic protein having SH-groups which are nitrosated, and of a compound containing thiol groups and having an average molecular weight of at most ~~10,000~~ 10,000 for the manufacture of a pharmaceutical combined preparation for the treatment of ischaemia and reperfusion injury, shock, in particular traumatic, hypovolaemic and haemorrhagic shock, respectively, or neurogenic shock, thrombotic conditions, respiratory tract diseases, erectile dysfunctions in men and hypertension.

2. (Currently Amended) The use according to claim 1, ~~characterized in that~~ wherein at least 90% of the present SH-groups are nitrosated.

3. (Currently Amended) The use according to ~~any of claims 1 or 2, characterized in that~~ claim 1, wherein at least one of S-nitroso albumin, S-nitroso orosomucoid, S-nitroso plasminogen activator, S-nitroso fibrinogen, S-nitroso Lys-plasminogen ~~or~~ and S-nitroso haemoglobin is contained as the therapeutic protein having nitrosated SH-groups.

4. (Currently Amended) The use according to ~~any of claims 1 or 2, characterized in that~~ claim 1, wherein at least one of reduced glutathione, L-cysteine, N-acetyl cysteine, L-cysteinyl glycine, γ -glutamyl cysteine, penicillamine, penicillamide, N-acetyl penicillamine, N-acetyl penicillamide, homocysteine, captopril, dihydrolipoic acid ~~and/or~~ and the oxidized form thereof, which, after administration, is reduced in vivo, is/are contained as the compound containing thiol groups.

5. (Currently Amended) The use according to ~~any of claims 3 or 4, characterized in that~~
claim 3, wherein S-nitroso albumin is contained as the therapeutic protein having nitrosated
SH-groups, and reduced glutathione is contained as the compound containing thiol groups.

6. (Currently Amended) The use according to claim 4, ~~characterized in that~~ wherein a
compound occurring in human blood and tissue, in particular at least one of reduced glutathione,
L-cysteine, L-cysteinyl glycine, γ -glutamyl cysteine ~~or~~ and dihydrolipoic acid, is contained as
the compound containing thiol groups.

7. (Currently Amended) The use according to ~~any of claims 1 to 6, characterized in that~~
claim 1, wherein a therapeutic protein obtained by nitrosation is contained in which the degree of
nitrosation is made up of S-nitrosation by at least 90% and of N,O,C-nitrosation by at most 10%.

8. (New) The use according to claim 2, wherein at least one of S-nitroso albumin,
S-nitroso orosomucoid, S-nitroso plasminogen activator, S-nitroso fibrinogen, S-nitroso
Lys-plasminogen and S-nitroso haemoglobin is contained as the therapeutic protein having
nitrosated SH-groups.

9. (New) The use according to claim 2, wherein at least one of reduced glutathione,
L-cysteine, N-acetyl cysteine, L-cysteinyl glycine, γ -glutamyl cysteine, penicillamine,
penicillamide, N-acetyl penicillamine, N-acetyl penicillamide, homocysteine, captopril,
dihydrolipoic acid and the oxidized form thereof, which, after administration, is reduced in vivo,
is/are contained as the compound containing thiol groups.

10. (New) The use according to claim 4, wherein S-nitroso albumin is contained as the therapeutic protein having nitrosated SH-groups, and reduced glutathione is contained as the compound containing thiol groups.

11. (New) The use according to claim 8, wherein S-nitroso albumin is contained as the therapeutic protein having nitrosated SH-groups, and reduced glutathione is contained as the compound containing thiol groups.

12. (New) The use according to claim 9, wherein S-nitroso albumin is contained as the therapeutic protein having nitrosated SH-groups, and reduced glutathione is contained as the compound containing thiol groups.

13. (New) The use according to claim 9, wherein a compound occurring in human blood and tissue, in particular at least one of reduced glutathione, L-cysteine, L-cysteinyl glycine, γ -glutamyl cysteine and dihydrolipoic acid, is contained as the compound containing thiol groups.

14. (New) The use according to claim 2, wherein a therapeutic protein obtained by nitrosation is contained in which the degree of nitrosation is made up of S-nitrosation by at least 90% and of N,O,C-nitrosation by at most 10%.

15. (New) The use according to claim 3, wherein a therapeutic protein obtained by nitrosation is contained in which the degree of nitrosation is made up of S-nitrosation by at least 90% and of N,O,C-nitrosation by at most 10%.

16. (New) The use according to claim 4, wherein a therapeutic protein obtained by nitrosation is contained in which the degree of nitrosation is made up of S-nitrosation by at least 90% and of N,O,C-nitrosation by at most 10%.

17. (New) The use according to claim 5, wherein a therapeutic protein obtained by nitrosation is contained in which the degree of nitrosation is made up of S-nitrosation by at least 90% and of N,O,C-nitrosation by at most 10%.

18. (New) The use according to claim 6, wherein a therapeutic protein obtained by nitrosation is contained in which the degree of nitrosation is made up of S-nitrosation by at least 90% and of N,O,C-nitrosation by at most 10%.